Paul studied Natural Sciences at the University of Cambridge, and stayed on at Cambridge to complete a PhD in the Department of Genetics. He carried out post-doctoral research in developmental neurobiology and neuroscience at King's College London and the University of Oxford, and spent two years in the biotech industry. Paul found science communication to be the most rewarding aspect of these roles, and enjoys explaining complex concepts clearly and compellingly.
Since moving into medical communications, Paul has gained substantial experience in health economics and outcomes research, and has developed health technology assessment submissions and global value dossiers as well as traditional medical communications. Paul has worked in a range of disease areas; he has particular expertise in oncology, ophthalmology and neurology but always enjoys learning about new therapy areas!
Selected publications
Endometrial hyperplasia in pre-menopausal women: a systematic review of incidence, prevalence, and risk factors
Petersdorf K, Groettrup-Wolfers E, Overton PM, Seitz C, Schulze-Rath R
European Journal of Obstetrics & Gynecology and Reproductive Biology 2022; 271; 158–171
Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review
Overton PM, Shalet N, Somers F, Allen JA
Patient Preference and Adherence 2021; 15: 811–834
Defining innovation with respect to new medicines: a systematic review from a payer perspective
de Solà-Morales O, Cunningham D, Flume M, Overton PM, Shalet N, Capri S
International Journal of Technology Assessment in Health Care 2018; 34: 224–240
Defining and measuring the affordability of new medicines: a systematic review
Antoñanzas F, Terkola R, Overton PM, Shalet N, Postma M
Pharmacoeconomics 2017; 35: 777–791
